MYRIAD GENETICS INC. - COMMON STOCK

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

28 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

19 Jul 2022 17:07:33 By Nasdaq GlobeNewswire

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

12 Jul 2022 16:12:38 By Nasdaq GlobeNewswire

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

28 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

23 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

09 Jun 2022 17:30:00 By Nasdaq GlobeNewswire

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

26 May 2022 18:30:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

05 May 2022 09:00:02 By Nasdaq GlobeNewswire

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

04 May 2022 16:05:02 By Nasdaq GlobeNewswire

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

03 May 2022 16:15:00 By Nasdaq GlobeNewswire